STOCK TITAN

Lantern Pharma Inc. - LTRN STOCK NEWS

Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.

Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.

Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.

In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.

With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.

Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced an extension of its share repurchase program through July 31, 2022, allowing for the acquisition of up to $7 million in common stock. Since November 2021, the program has seen the repurchase of 475,157 shares at a cost of approximately $3.4 million. An additional $3.6 million is available for future purchases. As of December 31, 2021, the company reported $70.7 million in cash and equivalents, indicating strong liquidity to support the buyback initiative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
buyback
-
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced promising preclinical data for its drug candidate LP-184 at the upcoming AACR annual meeting, scheduled for April 8-13, 2022. LP-184 showed significant anti-tumor activity in brain metastases models from lung, skin, and breast cancers, achieving 6 times greater potency than standard therapies. This small molecule drug targets DNA in cancer cells, particularly beneficial for patients with CNS cancers due to its favorable blood-brain barrier permeability. The FDA has granted LP-184 Orphan Drug and Rare Pediatric Disease designations, expediting its path toward clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
conferences clinical trial
-
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) reported its financial results for Q4 and the fiscal year 2021, marking a pivotal year with significant growth and clinical advancements. The RADR® A.I. platform achieved a remarkable 1,000% growth, surpassing 18 billion data points, and is projected to exceed 25 billion by the end of 2022. The company plans to initiate multiple clinical trials in 2022, including the Phase 2 trial for LP-300 in non-small cell lung cancer. Lantern raised $69 million in 2021, extending its cash runway into 2025, while reporting a net loss of $12.4 million for the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
Rhea-AI Summary

Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, will hold a conference call on March 10, 2022, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2021 financial results. Management, led by CEO Panna Sharma, will provide insights into the company's operating performance and guidance on upcoming milestones. Lantern Pharma specializes in oncology drug development leveraging its RADR® A.I. platform to enhance patient targeting for drug trials. The call will also be available via a replay on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
conferences earnings
-
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Greehey Children's Cancer Research Institute to expand its drug candidates, LP-184 and LP-284, into rare pediatric cancers. This partnership aims to validate findings from the RADR® platform and advance treatments for difficult-to-treat tumors like rhabdomyosarcoma and ATRT. The collaboration leverages GCCRI's expertise and models, seeking to accelerate pediatric cancer therapy development at reduced costs. Lantern has previously received FDA orphan drug designations for LP-184.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.09%
Tags
none
-
Rhea-AI Summary

Lantern Pharma (LTRN) announced that the FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation for its drug candidate LP-184, aimed at treating pediatric patients with ATRT (Atypical Teratoid Rhabdoid Tumor). LP-184 is also being investigated for genetically defined solid tumors like pancreatic cancer and GBM. The Rare Pediatric Disease designation may allow Lantern to receive a priority review voucher for future product applications. The firm focuses on using its RADR® A.I. platform to identify effective treatments tailored to patient genetics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Danish Cancer Society Research Center to advance clinical development of its drug candidates, LP-100 and LP-184. This partnership aims to enhance diagnostic methods for identifying NER-deficient tumors. The collaboration will leverage Lantern's RADR® AI platform, potentially adding millions of data points and expediting cancer treatment discovery. Both LP-100 and LP-184 have shown promise in targeting NER deficiencies, with LP-100 currently in a phase 2 trial for metastatic prostate cancer, showing improved overall survival rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
-
Rhea-AI Summary

Lantern Pharma (LTRN) has expanded its collaboration with the National Cancer Institute (NCI) to enhance the development of its oncology drug candidates, LP-184 and LP-284. This partnership aims to leverage multiomic data to identify gene signatures predicting tumor responses. LP-184 is targeting pancreatic cancer and glioblastoma, while LP-284 focuses on leukemias and lymphomas. Initial results suggest LP-184 may be more effective in tumors resistant to current treatments. The partnership will continue to refine predictive biomarkers and advance clinical trials, with results expected to be published in peer-reviewed journals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
-
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO Panna Sharma will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be a fireside chat with analyst Michael King and will be available on-demand for attendees starting January 10 at 7:00 AM ET. Lantern Pharma utilizes its RADR® A.I. platform for oncology drug development, focusing on biomarker identification to enhance treatment outcomes for patients. More information can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
conferences
Rhea-AI Summary

On December 14, 2021, Lantern Pharma (NASDAQ: LTRN) announced positive data on LP-284's efficacy against hematologic cancers presented at the ASH Annual Meeting. LP-284, a synthetic acylfulvene compound, showcased broad anti-tumor activity against lymphoma, multiple myeloma, and leukemia in vitro. The findings suggest LP-284 could serve as a targeted therapy option for cancers with DNA repair deficiencies. Lantern plans to leverage its RADR® A.I. platform to advance LP-284 development and address the urgent need for new treatment options in blood cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none

FAQ

What is the current stock price of Lantern Pharma (LTRN)?

The current stock price of Lantern Pharma (LTRN) is $3.145 as of December 20, 2024.

What is the market cap of Lantern Pharma (LTRN)?

The market cap of Lantern Pharma (LTRN) is approximately 35.4M.

What does Lantern Pharma Inc. specialize in?

Lantern Pharma specializes in precision medicine for cancer treatment, using AI and ML to identify and treat patients who will benefit most from their therapies.

What is the RADR platform?

RADR is Lantern Pharma's proprietary AI and ML platform that uses oncology-focused data points and advanced algorithms to accelerate cancer drug development.

How does Lantern Pharma's approach reduce drug development costs?

By using biomarker-based genetic screening to target patients more likely to respond to their drugs, Lantern Pharma decreases the cost and time required for drug development.

What is the company's strategy for growth?

Lantern Pharma focuses on acquiring or partnering with promising drug and diagnostic companies to advance personalized medicine programs for cancer patients.

How does Lantern Pharma use AI in drug development?

The company uses its AI platform, RADR, to analyze oncology data and develop precision therapies more efficiently and accurately.

Who are the key collaborators with Lantern Pharma?

Lantern Pharma collaborates with world-class scientific advisors and partners to enhance its precision medicine initiatives.

What are some of Lantern Pharma's recent achievements?

Lantern Pharma has made significant advances in its precision therapies and expanded its pipeline, leveraging AI to address real-world cancer treatment challenges.

Why is precision medicine important in cancer treatment?

Precision medicine allows for more accurate targeting of treatments based on genetic markers, improving efficacy and reducing unnecessary side effects.

How does Lantern Pharma's strategy benefit cancer patients?

By focusing on precision medicine and AI, Lantern Pharma aims to deliver more effective treatments faster and at a lower cost, benefiting patients with more tailored therapies.

What is the significance of biomarker-based genetic screening?

Biomarker-based genetic screening helps identify patients who are most likely to benefit from specific treatments, improving the chances of successful outcomes.

Lantern Pharma Inc.

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

35.42M
9.20M
14.75%
24.1%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DALLAS